Cell-based therapies for cardiac disease: A cellular therapist's perspective

Transfusion

Volumn 55, Issue 2, 2015, Pages 441-451

  Young, Pampee P ^a,b,c   Schäfer, Richard ^d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; BONE MARROW DERIVED MONONUCLEAR CELL; CARDIAC STEM CELL; CELL DIFFERENTIATION; CELL RENEWAL; CELL SURVIVAL; CELL THERAPY; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIAL PROGENITOR CELL; FOLLOW UP; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CELL; HUMAN; IN VITRO STUDY; META ANALYSIS; MYOBLAST; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; THERAPY EFFECT; TREATMENT OUTCOME; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); HEART DISEASES; HEART MUSCLE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROCEDURES;

CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIUM;

EID: 84923041304     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12826     Document Type: Review

References (58)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-220.
2. Topol EJ,. Current status and future prospects for acute myocardial infarction therapy. Circulation 2003; 108: III6-13.
3. Sharpe N,. Cardiac remodeling in coronary artery disease. Am J Cardiol 2004; 93: 17B-20B.
4. Schoenfeld M, Frishman WH, Leri A, et al. The existence of myocardial repair. Cardiol Rev 2013; 21: 111-120.
5. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705.
6. Fuchs S, Baffour R, Zhou F, et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001; 37: 1725-1732.
7. de Silva R, Raval AN, Hadi M, et al. Intracoronary infusion of autologous mononuclear cells from bone marrow or granulocyte colony-stimulating factor-mobilized apheresis product may not improve remodelling, contractile function, perfusion, or infarct size in a swine model of large myocardial infarction. Eur Heart J 2008; 29: 1772-1782.
8. Moelker AD, Baks T, van den Bos EJ, et al. Reduction in infarct size, but no functional improvement after bone marrow cell administration in a porcine model of reperfused myocardial infarction. Eur Heart J 2006; 27: 3057-3064.
9. Schuleri KH, Feigenbaum GS, Centola M, et al. Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J 2009; 30: 2722-2732.
10. Johnston PV, Sasano T, Mills K, et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation 2009; 120: 1075-1083.
11. Lee S, White AJ, Matsushita S, et al. Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 2011; 57: 455-465.
12. Sanganalmath SK, Bolli R,. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013; 113: 810-834.
13. Strauer BE, Brehm M, Zeus T, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-1918.
14. Perin EC, Dohmann HF, Borojevic R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294-2302.
15. van Ramshorst J, Bax JJ, Beeres SA, et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009; 301: 1997-2004.
16. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117: 1189-1200.
17. Veltman CE, Soliman O II, Geleijnse ML, et al. Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy. Eur Heart J 2008; 29: 1386-1396.
18. Duckers HE, Houtgraaf J, Hehrlein C, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention 2011; 6: 805-812-DOI10.
19. Povsic TJ, O'Connor CM, Henry T, et al. A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 2011; 162: 654-662.
20. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221.
21. Lunde K, Solheim S, Aakhus S, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-1209.
22. Janssens S, Dubois C, Boggaert J, et al. Autologous bone marrow-derived stem cell transfer in patients with ST-segment elevation myocardial infarction: double blind, randomized controlled trial. Lancet 2006; 364: 141-148.
23. Roncalli J, Mouquet F, Piot C, et al. Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. Eur Heart J 2011; 32: 1748-1757.
24. Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mnocuclear cells on functional capacity, left ventricular function and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA 2012; 307: 1717-1726.
25. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287-1294.
26. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8: 105-110.
27. Assmus B, Fischer-Rasokat U, Honold J, et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry. Circ Res 2007; 100: 1234-1241.
28. Zhang C, Sun A, Zhang S, et al. Efficacy and safety of intracoronary autologous bone marrow-derived cell transplantation in patients with acute myocardial infarction: insights from randomized controlled trials with 12 or more months follow-up. Clin Cardiol 2010; 33: 353-360.
29. Tian T, Chen B, Xiao Y, et al. Intramyocardial autologous bone marrow cell transplantation for ischemic heart disease: a systematic review and meta-analysis of randomized controlled trials. Atherosclerosis 2014; 233: 485-492.
30. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the Late TIME randomized trial. JAMA 2011; 306: 2110-2119.
31. Traverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA 2012; 308: 2380-2389.
32. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012; 308: 2369-2379.
33. Ascheim DD, Gelijns AC, Goldstein D, et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 2014; 129: 2287-2296.
34. Houtgraaf JH, den Dekker WK, van Dalen BM, et al. First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2012; 59: 539-540.
35. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchyamal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
36. Siegel G, Kluba T, Hermanutz-Klein U, et al. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med 2013; 11: 146-149.
37. Churchman SM, Ponchel F, Boxall SA, et al. Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. Arthritis Rheum 2012; 64: 2632-2643.
38. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure. J Am Coll Cardiol 2013; 61: 2329-2338.
39. Siegel G, Krause P, Wohrle S, et al. Bone marrow derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev 2012; 21: 2457-2470.
40. Rose RA, Jiang H, Wang X, et al. Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. Stem Cells 2008; 26: 2884-2892.
41. Chugh AR, Beache GM, Loughran JH, et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 2012; 126: S54-64.
42. Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012; 379: 895-904.
43. Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1 year results of CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 2014; 63: 110-122.
44. Marbán E, Malliaras K, Smith RR, et al. Cardiosphere-derived cells for heart regeneration-Authors' reply. Lancet 2012; 379: 2426-2427.
45. Dimmeler S, Zeiher AM, Schneider MD,. Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest 2005; 115: 572-583.
46. Williams AR, Hare JM,. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 2011; 109: 923-940.
47. Schäfer R, Northoff H,. Cardioprotection and cardiac regeneration by mesenchymal stem cells. Panminerva Med 2008; 50: 31-39.
48. Timmers L, Lim SK, Arslan F, et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res 2007; 1: 129-137.
49. Timmers L, Lim SK, Hoefer IE, et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011; 6: 206-214.
50. Kumar AH, Caplice NM,. Clinical potential of adult vascular progenitor cells. Arterioscler Thromb Vasc Biol 2010; 30: 1080-1087.
51. Alfaro MP, Young PP,. Lessons from genetically altered mesenchymal stem cells (MSCs); candidates for improved MSC-directed myocardial repair. Cell Transplant 2012; 21: 1065-1074.
52. Phinney DG, Sensebe L,. Mesenchymal stromal cells: misconceptions and evolving concents. Cytotherapy 2013; 15: 140e.
53. Lee MH, Arcidiacono JA, Bilek AM, et al. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. Tissue Eng 2010; 16: 41-54.
54. Lysaght T, Campbell AV,. Regulating autologous adult stem cells: the FDA steps up. Cell Stem Cell 2011; 9: 393-396.
55. Bolli R, Chugh AR, D'Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011; 378: 1847-1857.
56. Chen AF, Ting S, Seow J, et al. Considerations in designing systems for large scale productin of human cardiomyocytes from pluriptent stem cells. Stem Cell Res Ther 2014; 5: 12-25.
57. Lecina M, Ting S, Choo A, et al. Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures. Tissue Eng Part C Methods 2010; 16: 1609-1619.
58. Behfar A, Crespo-Diaz R, Terzic A, et al. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol 2014; 11: 232-246.